Research Article

Association of Serum Homocysteine with Cardiovascular and All-Cause Mortality in Adults with Diabetes: A Prospective Cohort Study

Jingtong Lu,1,2,3 Kegong Chen,4 Wei Chen,1,2 Chang Liu,2 XingPei Jiang,1,2 Zili Ma,1,2 Dong Li,1,2 Yanjiao Shen,5,6 and Hai Tian1,2

1Department of Cardiovascular Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
2Future Medical laboratory, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
3Department of Thoracic Surgery, The Third Hospital of Xiamen, Xiamen, China
4Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China
5Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China
6Medical Device Regulatory Research and Evaluation Centre, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Correspondence should be addressed to Yanjiao Shen; yanjiaoshen009@outlook.com and Hai Tian; doctor_tianhai@163.com

Received 2 April 2022; Revised 28 July 2022; Accepted 8 September 2022; Published 11 October 2022

Academic Editor: Chan-Yen Kuo

Copyright © 2022 Jingtong Lu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Homocysteine (Hcy) was implicated in oxidative stress and diabetes biologically. However, the clinical evidence on the link between Hcy level and diabetes is limited and controversial. This study is aimed at investigating the association of serum Hcy with all-cause and cardiovascular mortality in diabetic patients. Methods. Serum Hcy was measured among 2,286 adults with type 2 diabetes in NHANES 1999-2006. Cox proportional hazard regression was used to estimate hazard ratios (HR) and 95% CIs for the association of Hcy with all-cause and cause-specific mortality. Results. Over a median follow-up of 11.0 (interquartile range, 8.9-13.4) years, 952 of the 2286 patients with diabetes died, covering 269 (28.3%) cardiovascular deaths and 144 (15.2%) cancer deaths. Restricted cubic spline showed the linear relationship between Hcy and all-cause mortality risk. After multivariate adjustment, higher serum Hcy levels were independently associated with increased risk of all-cause and cardiovascular mortality. Compared with participants in the bottom tertile of Hcy, the multivariate-adjusted HRs and 95% CI for participants in the top quartile were 2.33 (1.64-3.30) for all-cause mortality (p trend <0.001), 2.24 (1.22-4.10) for CVD mortality (P tend = 0.017), and 2.05 (0.90-4.69) for cancer mortality (p trend = 0.096). The association with total mortality was especially stronger among patients with albuminuria. Serum Hcy significantly improved reclassification for 10-year mortality in diabetic patients (net reclassification index = 0.253 and integrated discrimination improvement = 0.011). Conclusions. Serum Hcy was associated with risks of all-cause and cardiovascular mortality in diabetic adults. Our results suggested that Hcy was a promising biomarker in risk stratification among diabetic patients.

1. Introduction

The incidence of diabetes mellitus and diabetic complications was rapidly increasing, affecting more than 400 million people worldwide [1, 2]. Cardiovascular disease (CVD) remains as the major cause of morbidity and mortality in diabetic patients [3]. The American Diabetes Association (ADA) recently underlines the necessity to improve risk stratification and enable individualized treatment to early prevent morbidity and mortality [4]. Plasma haemoglobin A1c (HbA1c) is of limited prognostic value since it only reflects glucose level over the preceding three months, which cannot develop an effective association with the long-lasting accumulated effects of disease progression [5]. Novel prognostic biomarkers remained required in the management of diabetic patients [6].
Homocysteine (Hcy) is a sulfur-containing amino acid, an intermediate product generated from the metabolism of methionine which is metabolized either by the remethylation process or by the transsulfuration pathway [7, 8]. Numerous studies demonstrated that an increase in serum Hcy was a strong risk factor for cardiovascular diseases [9]. According to a recent meta-analysis, the risk of CVD or stroke was elevated by 10% and 20%, respectively, for each 25% increase in plasma Hcy [10]. Similarly, with a 5 μmol/L increase in Hcy levels, the risk of incident heart disease increased by 52% and mortality increased by 32% [11]. Biologically, Hcy may drive the process of CVD through various mechanisms including blood coagulant properties and oxidative stress-inducing injuries of vascular endothelium and arterial walls [12, 13]. However, most of the evidence was concluded in the nondiabetic setting.

Serum Hcy may be a promising biomarker of vascular complications in diabetes [14]. Several clinical studies indicated that Hcy level was associated with the risk of atherosclerosis and CVD in patients with type 2 diabetes mellitus [12, 14]. However, some studies did not note a robust association between Hcy level and diabetes or diabetic complications [15, 16]. In particular, whether serum Hcy predicts mortality risk in diabetic patients was unclear. Given this context, this study is aimed at investigating the relationship between serum Hcy and the risk of all-cause and cause-specific mortality and evaluated the additional predictive value of Hcy for risk stratification of long-term mortality among patients with type 2 diabetes based on a nationally representative sample [17].

2. Research Design and Methods

2.1. Study Population. Participants in this study were included in the National Health and Nutrition Examination Surveys (NHANES), a stratified and multistage probability sampling study, as described in others and our previous studies [18–20]. NHANES was a nationally representative study of the civilian noninstitutionalized US population of all ages to assess the health and nutritional condition. The protocols and methods of sampling weight and data collection have been published elsewhere [21]. Serum Hcy was determined in four study cycles of NHANES (1999-2000, 2001-2002, 2003-2004, and 2005-2006). Diabetes was defined as a self-reported diagnosis by a doctor, plasma HbA1c ≥ 6.5%, or fasting glucose ≥ 7.0 mmol/L. Among 20,311 adults aged ≥20 years, 2,569 individuals were diagnosed with diabetes. We excluded diabetic adults with pregnancy (n = 13), without data on serum Hcy (n = 268), and loss of follow-up (n = 2). Finally, 2,286 adults with diabetes were included (Figure 1). This study was approved by the research ethics review board of the Centers for Disease Control and Prevention, and all participants provided written informed consent.

2.2. Study Exposure: Measurement of Serum Hcy. Serum homocysteine (Hcy) was measured by the Abbott Homocysteine assay, a fully automated fluorescence polarization immunoassay (FPIA) method. Dithiothreitol (DTT) was used to reduce the disulfide bond to albumin and other molecules to free thiol. S-Adenosyl-homocysteine (SAH) hydrolase catalyzes the conversion of Hcy to SAH in the presence of added adenosine. The specific monoclonal antibody and the fluoresceinlabeled SAH analog tracer constitute the FPIA detection system. Hcy level was calculated by the Abbott Axsym® using a machine-stored calibration curve (r² = 0.999). This method is linear for homocysteine in the range of 0.8-50 μmol/L with a total coefficient of variation in the range of 3-6%. Samples with results < 2 μmol/L or > 15 μmol/L are reanalyzed for confirmation. Samples with total homocysteine concentrations > 50 μmol/L are diluted 10-fold with PBS or FPIA buffer and reanalyzed.

2.3. Definition of Covariates. Age, sex, race/ethnicity, smoking status, self-reported cardiovascular disease, cancer, and diabetes-related features and medications at baseline were collected from household interviews using standardized questionnaires [18]. Self-reported cardiovascular disease consisted of coronary heart disease, myocardial infarction, heart failure, and stroke. Duration of diabetes and diabetic peripheral complications (diabetic ulcer/sore, neuropathesia, or retinopathy) were extracted from diabetic questionnaires [22]. Prescribed medications were recorded during the preceding 30 days. The examination was performed according to standardized protocols and processes. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters) squared. Hypertension was defined as antihypertensive treatment, the average systolic blood pressure ≥ 140 mmHg or the diastolic blood pressure ≥ 90 mmHg at baseline [22]. Blood and urine samples were collected, processed, and transported to central laboratories following validated procedures. Laboratory data on total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), HbA1c, creatinine, and vitamin B12 were acquired in all cycles. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration using serum creatinine. Urine albumin and creatinine levels were tested with a fluorescent immunoassay and Jaffe rate reaction, respectively. Urine albumin excretion was calculated as urine albumin divided by urine creatinine which was presented as the urine albumin-creatinine ratio (UACR, mg/g) [22].

2.4. Study Outcomes. All-cause and cause-specific mortalities were ascertained by the National Death Index with a unique sequence number in the National Center for Health Statistics of US through December 31, 2015 [19]. The leading cause of death was identified using the International Classification of Diseases 10th Revision (ICD-10), including death due to cardiovascular disease (I00-I09, I11, I13, I20-I51, and C00-C97) and malignant neoplasms (C00-C97). The follow-up time was defined from baseline until death or the end of follow-up.

2.5. Statistical Analysis. Clustering, stratification, and sampling weights were used to ensure nationally representative estimates according to the analytical guidelines of the NHANES study unless otherwise noted [23]. Baseline
characteristics are expressed as weighted means and percent-
ages. The trend of baseline characteristics across the Hcy
quartiles was tested by weighted linear regression or logis-
tics regression. Restricted cubic spline based on age- and
gender-adjusted Cox proportional hazard model was used
to visualize the linear or nonlinear association between
serum Hcy and all-cause mortality. Weighted Kaplan-
Meier plots were used to visualize all-cause mortality
across Hcy strata. Hazard ratios (HRs) and 95% CI for
total or cause-specific mortality were assessed by weighted
Cox proportional hazard models. Two adjusted models
were applied. Model 1 was adjusted for age and sex.
Model 2 was further adjusted for race/ethnicity (white,
black, Hispanic-Mexican, or other), smoking status (never,
quitting and current smoking), BMI, hypertension, cancer,
CVD, the ratio of TC/HDL-C, vitamin B12, eGFR, plasma
HbA1c, metformin, duration of diabetes, UACR, ACEI/
ARBs, and diabetic complications. The proportional haz-
ard assumption by estimation of Schoenfeld’s residuals
was fulfilled for Cox regression model.

In secondary analyses, the association between baseline
Hcy and total mortality was ascertained in subgroups by
age (<65 and ≥65 years), sex (female and male), B12 (<400
and ≥400 pmol/L), metformin use (no/yes), UACR (<30
and ≥30 mg/g), eGFR (≥ 60 and <60 mL/min/1.73m²), dura-
tion of diabetes (<10 and ≥10 years), and HbAc1(< 8% and
≥8%) with the fully adjusted model except for stratification
factors. The survey-weighted Wald test was adopted to
assess the potential interaction.

Several sensitivity analyses were conducted. First, we
excluded patients with probable type 1 diabetes who was
aged <30 years when first diagnosed as diabetes. Second,
we further examined the associations of Hcy with mortality
after excluding adults who are first diagnosed with diabetes.
The prediction value of Hcy for 10-year total and heart-
specific mortality was assessed in NHANES 1999-2006 via
unweighted Cox regression. The reference model was built
with currently traditional risk factors, consisting of age,
sex, current smoking, BMI, hypertension, cancer, cardiovas-
cular disease, the ratio of TC/HDL-C, eGFR, UACR, HbAc1,
diabetic duration, and diabetic complication. The goodness
of fit was determined using the likelihood ratio (LR) test,
Akaike information criterion (AIC), and Bayesian information
criterion (BIC). Harrell’s C-index, net reclassification
improvement (NRI), and integrated discrimination
improvement (IDI) were adopted to assess the incremental
discrimination capacity of Hcy based on the reference model
[19]. All tests with 2-sided p < 0.05 were considered statisti-
cally significant using Stata (version 12).

3. Results

3.1. Participant Characteristics. We investigated serum Hcy
in 2,286 patients with type 2 diabetes mellitus. The mean
age was 58.9 years, and 50.0% were male diabetic adults.
The weighted mean level of serum Hcy was 9.94 (95% CI,
9.62-10.25) μmol/L and skewed distribution (Supplementary
Figure 1). Hcy levels were comparable across study years and
gender (Supplementary Figure 2). Baseline characteristics of
diabetic patients across the quartiles of Hcy levels (Q1: ≤7.34,
Q2: 7.33-9.22, Q3: 9.22-11.73, and Q4: >11.73 μmol/L
were presented in Table 1. The patients in higher
quartiles were more often older, non-Hispanic whites, and
quit smoking and more likely to suffer from chronic
Table 1: Baseline characteristics of diabetic patients across quartiles of serum homocysteine.

| Variables                      | Quartile 1 (n = 574) | Quartile 2 (n = 569) | Quartile 3 (n = 574) | Quartile 4 (n = 569) | p for trend |
|-------------------------------|----------------------|----------------------|----------------------|----------------------|-------------|
| Homocysteine (μmol/L)         | 6.14 ± 0.05          | 8.26 ± 0.03          | 10.39 ± 0.05         | 16.67 ± 0.41         | <0.001      |
| Age (years)                   | 50.21 ± 0.88         | 58.14 ± 0.76         | 62.92 ± 0.73         | 66.72 ± 0.81         | <0.001      |
| Male (%)                      | 36.6                 | 51.35                | 55.54                | 59.59                | <0.001      |
| Race/ethnicity (%)            |                      |                      |                      |                      |             |
| Non-Hispanic white            | 53.04                | 66.18                | 66.6                 | 69.64                | <0.001      |
| Non-Hispanic black            | 15.51                | 13.58                | 14.23                | 18.48                | 0.270       |
| Hispanic-Mexican              | 13.18                | 6.842                | 6.373                | 4.386                | <0.001      |
| Other ethnicity               | 18.26                | 13.4                 | 12.8                 | 7.496                | <0.001      |
| Smoking status                |                      |                      |                      |                      | <0.001      |
| Never smoking                 | 60.07                | 47.05                | 42.28                | 39.35                |             |
| Former smoker                 | 22.25                | 33.85                | 36.48                | 43.65                |             |
| Current smoker                | 17.68                | 19.1                 | 21.23                | 17                   |             |
| Physical activity (%)         |                      |                      |                      |                      | <0.001      |
| Inactive                      | 43.59                | 49.98                | 49.47                | 65.81                |             |
| Moderate activity             | 30.07                | 31.61                | 33.15                | 27.5                 |             |
| Vigorous activity             | 26.34                | 18.41                | 17.39                | 6.69                 |             |
| BMI (kg/m²)                   | 33.20 ± 0.45         | 32.78 ± 0.42         | 31.41 ± 0.39         | 31.41 ± 0.50         | 0.001       |
| Hypertension (%)              | 54.24                | 69.98                | 72.39                | 80.75                | <0.001      |
| Waist circumference (cm)      | 108.36 ± 1.05        | 109.66 ± 0.90        | 108.33 ± 0.93        | 109.04 ± 1.09        | 0.860       |
| Cardiovascular disease (%)    | 12.65                | 23.12                | 31.09                | 44.03                | <0.001      |
| Cancer (%)                    | 7.008                | 14.68                | 15.1                 | 17.04                | <0.001      |
| TC/HDL-C ratio                | 2.2 ± 0.10           | 2.3 ± 0.23           | 2.28 ± 0.18          | 2.29 ± 0.17          | 0.672       |
| HbA1c (%)                     | 7.76 ± 0.13          | 7.41 ± 0.08          | 7.29 ± 0.12          | 6.98 ± 0.10          | <0.001      |
| Plasma glucose (mmol/L)       | 9.10 ± 0.22          | 8.40 ± 0.18          | 8.06 ± 0.25          | 7.97 ± 0.21          | <0.001      |
| Insulin (pmol/L)              | 120.92 ± 7.53        | 151.48 ± 21.50       | 131.63 ± 10.63       | 140.78 ± 10.55       | 0.340       |
| HbA1c (mmol/mol)              | 61.36 ± 1.42         | 57.49 ± 0.88         | 56.16 ± 1.31         | 52.79 ± 1.06         | 0.001       |
| eGFR (mL/min per 1.73m²)      | 102.88 ± 1.23        | 89.95 ± 0.99         | 78.69 ± 1.31         | 61.02 ± 1.34         | <0.001      |
| UACR (mg/g)                   | 72.33 ± 22.72        | 117.03 ± 23.07       | 110.76 ± 18.86       | 310.24 ± 47.51       | <0.001      |
| C-reactive protein (mg/dL)    | 0.78 ± 0.06          | 0.72 ± 0.07          | 0.57 ± 0.04          | 0.70 ± 0.06          | 0.085       |
| C-peptide (nmol/L)            | 1.17 ± 0.10          | 1.25 ± 0.06          | 1.07 ± 0.06          | 1.30 ± 0.07          | 0.653       |
| Metformin use (%)             | 34.17                | 31.14                | 33.4                 | 25.72                | 0.041       |
| Diabetic complications (%)    | 31.57                | 33.75                | 36.92                | 47.82                | <0.001      |
| Retinopathy (%)               | 16.99                | 19.26                | 17.23                | 25.32                | 0.021       |
| Foot ulcer (%)                | 4.41                 | 2.746                | 6.855                | 9.399                | 0.006       |
| Peripheral neuropathy (%)     | 19.53                | 21.6                 | 25.06                | 31.77                | 0.001       |
| Duration of diabetes (year)   | 7.84 ± 0.53          | 7.83 ± 0.54          | 9.67 ± 0.79          | 12.24 ± 0.92         | <0.001      |
| Serum B12 (pmol/mL)           | 529.15 ± 60.63       | 410.56 ± 10.52       | 376.62 ± 10.63       | 432.16 ± 73.35       | 0.189       |
| Serum folate (nmol/L)         | 38.11 ± 2.67         | 38.34 ± 3.58         | 37.48 ± 1.52         | 36.91 ± 1.87         | 0.653       |

Data are represented as the weighted proportion (%) or mean ± SE. p for trend was estimated with linear regression for continuous variables and with logistic regression for categorical variables. BMI: body mass index; CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate; HDL-C: high-density lipoprotein cholesterol; HOMA-IR: homeostasis model assessment for insulin resistance; Hcy: homocysteine; TC: total cholesterol; UACR: urinary albumin-creatinine ratio.

disease, including prior cardiovascular disease, cancer, hypertension, and diabetic complications. They also had a longer duration of diabetes, higher UCAR, and lower eGFR.

### 3.2. Correlation between Hcy and Cardiometabolic Biomarkers

Partial correlation coefficients after adjustment for age, sex, and race were used to assess the correlation...
Weighted multivariable Cox regression analyses were used to assess mortality risk associated with Hcy (Table 3). Serum Hcy at baseline was significantly associated with a higher risk of all-cause, cardiovascular, and cancer-specific mortality, with HR (95% CI) per a doubling of Hcy 2.38 (1.88-3.00, \( p < 0.001 \)), 2.52 (1.91-3.33, \( p < 0.001 \)), and 1.93 (1.50-2.49, \( p < 0.001 \)), respectively. The age- and sex-adjusted HR per doubling Hcy for total and cardiovascular mortality was significant, while for cancer mortality, it was insignificant. After multivariate adjustment for the various confounders, the relationship between log2 transformed Hcy with all-cause and cardiovascular mortality remained significant (each \( p < 0.018 \), with a 61% and 53% increase in risk per a doubling of Hcy, respectively. Consistently, the mentioned associations across Hcy quartiles remained significant. The adjusted HRs (95% CIs) from the bottom quartile to the top quartile of serum Hcy were 1.00 (reference), 1.13 (0.82-1.57), 1.39 (1.03-1.88), and 2.33 (1.64-3.30) for all-cause mortality (\( p < 0.001 \)) and 1.00 (reference), 1.10 (0.65-1.88), 1.25 (0.74-2.12), and 2.24 (1.22-4.10) for CVD mortality (each \( p \) trend \( < 0.017 \)). The increased cardiovascular mortality associated with higher Hcy was mainly attributed to heart disease (Supplementary Table 1). By contrast, the association between mortality due to cancer and Hcy quartiles was insignificant.

3.4. Stratification and Additional Analyses. In stratified analyses, the association of serum Hcy at baseline with increased risk of all-cause mortality was largely consistent in most subgroups (Figure 3). A significant interaction in all-cause mortality was noted between serum Hcy and UACR (\( p \) for interaction = 0.002). The HRs per a doubling of Hcy for all-cause mortality were 1.43 (1.08-1.89) among patients with UACR <30 \( \mu \)g/mg versus 1.94 (1.52-2.48) among those with UACR \( \geq 30 \mu \)g/mg. However, there is no significant interaction in mortality between metformin use and serum Hcy.

Excluding individuals with probable type 1 diabetes who were diagnosed as diabetes before 20 years of age and treated with only insulin, a robust relationship between serum Hcy and mortality risk was still identified (Supplementary Table 2). We additionally excluded participants who were first diagnosed with diabetes and noted a significant relationship between serum Hcy and mortality (Supplementary Table 3). For sensitivity analysis, serum Hcy was categorized according to the predefined definition of hyperhomocysteinemia (>15 \( \mu \)mol/L), and the association remained statistically significant (Supplementary Table 4). Compared with diabetic patients with Hcy levels \( \leq 15 \mu \)mol/L, the adjusted HRs (95% CIs) for all-cause mortality among those with levels >15 \( \mu \)mol/L were 1.91 (1.47-2.48) and 2.37 (1.50-3.74), respectively (both \( p < 0.001 \)).

3.5. Prognostic Value of Serum Hcy. Using a single biomarker to predict 10-year mortality risk, Hcy had a larger area under the ROC curve than CRP (AUC-ROC 0.718 versus 0.525, Figure 4). Furthermore, the additional value of Hcy for risk prediction of long-term mortality was determined among
diabetic patients from NHANES 1999–2006 (Table 4). Adding Hcy to the reference model did not substantially increase Harrell’s C-index. A significant improvement in reclassification was noted when adding Hcy to the reference model for all-cause death as measured by NRI and IDI (0.253 and 0.011, respectively; \( p < 0.001 \) for the likelihood ratio test). However, CRP did not significantly improve predictive performance for mortality based on conventional clinical factors (NRI 0.188 and IDI 0.003, respectively; \( p = 0.074 \) for likelihood ratio test).

### 4. Discussion

This study investigated the association of serum Hcy with all-cause and cause-specific mortality in adults with type 2 diabetes. Serum Hcy was robustly associated with increased risk of all-cause and heart-related mortality after adjustment for traditional risk factors, whereas the incremental predictive value of Hcy for 10-year mortality risk was significantly on top of the common risk stratification model. To our best knowledge, this study initially demonstrated that Hcy...
concentration was independently associated with all-cause and cardiovascular mortality in diabetic adults, and Hcy provided an incremental prognostic value to predict long-term mortality beyond the well-established inflammation biomarker C-reactive protein.

The association between Hcy and mortality risk in diabetic patients has not been well established. A large number of previous studies have reported that Hcy was closely related to the development and progression of CVD, cancer, and neurodegenerative diseases [7, 9, 17, 24, 25]. However, most of the investigations concerning the clinical association between Hcy level and mortality risk were mainly reported in a nondiabetic setting [9, 20, 26]. According to the previous two pooled analyses for prospective cohort studies, increased concentrations of serum Hcy were an independent predictor of risks of cardiovascular and all-cause mortality, and the risk was more pronounced in the elderly [11, 27]. Further, the dose-response meta-analysis suggested that increased Hcy was linearly related to the risk of mortality in the general population, with all-cause mortality elevated by 33.6% for each 5 μmol/L increase of serum Hcy [27]. Consistently, among patients with acute coronary syndrome or stroke, elevated Hcy at baseline was also significantly associated with an increased risk of MACE and all-cause mortality [28]. The data on the relationship between Hcy levels and mortality risk in diabetic patients was limited. Looker et al. investigated the relationship between baseline Hcy and mortality during a median follow-up of 15.7 years among 396 diabetic Pima Indians aged 40 years or older [15]. Serum Hcy was positively associated with all-cause and diabetes-/nephropathy-associated mortality in adults with type 2 diabetes. After adjustment for creatinine and other confounders, the association between Hcy and mortality became nonsignificant. However, the population observed in this study was recruited between 1982 and 1985, and epidemiological characteristics of diabetes patients may vary over the past decades [1]. In addition, the study population was limited to Pima Indians which may limit the extrapolation. The higher correlation between Hcy and serum creatinine in their analysis (correlation coefficient = 0.50) than our study (correlation coefficient = 0.35) also supported this point. Ndrepepa et al. observed 507 patients with type 2 diabetes and coronary artery disease between 2000 and 2001 [29]. Although the K-M survival curve showed that accumulative cardiovascular mortality was increased in patients with higher Hcy, the relationship was

Table 3: HR (95% CI) associated with Hcy for all-cause, cardiovascular, and cancer mortality in adults with diabetes.

| All-cause deaths | Doubling in Hcy | p value | Q1 (n = 574) | Q2 (n = 569) | Q3 (n = 574) | Q4 (n = 569) | p for trend |
|------------------|----------------|---------|--------------|--------------|--------------|--------------|------------|
| Mortality rate per 1000 person-years | | | | | | | |
| Unadjusted model | 34.2 (31.5-37.3)* | 14.0 (11.1-18.0) | 26.3 (21.9-31.7) | 39.4 (33.8-46) | 81.3 (71.2-93.1) | | |
| Model 1 | 2.38 (1.88-3.00)* | <0.001 | 1 (ref.) | 1.93 (1.42-2.63) | 2.98 (2.24-3.97) | 6.46 (4.82-8.66) | <0.001 |
| Model 2 | 1.77 (1.44-2.17) | <0.001 | 1 (ref.) | 1.29 (0.94-1.77) | 1.63 (1.28-2.07) | 2.90 (2.19-3.84) | <0.001 |
| Model 3 | 1.61 (1.34-1.92) | <0.001 | 1 (ref.) | 1.13 (0.82-1.57) | 1.39 (1.03-1.88) | 2.33 (1.64-3.30) | <0.001 |

Cardiovascular deaths

| Cardiovascular deaths | Doubling in Hcy | p value | Q1 (n = 574) | Q2 (n = 569) | Q3 (n = 574) | Q4 (n = 569) | p for trend |
|----------------------|----------------|---------|--------------|--------------|--------------|--------------|------------|
| Mortality rate per 1000 person-years | | | | | | | |
| Unadjusted | 8.3 (11.4-11.4) | 4.0 (2.5-6.6) | 8.2 (6.1-11.4) | 9.6 (7.1-13.1) | 24.3 (19-31.5) | | |
| Model 1 | 2.52 (1.91-3.33) | <0.001 | 1 (ref.) | 2.15 (1.23-3.74) | 2.61 (1.44-4.73) | 7.00 (4.05-12.12) | <0.001 |
| Model 2 | 1.82 (1.34-2.48) | <0.001 | 1 (ref.) | 1.30 (0.75-2.26) | 1.20 (0.66-2.17) | 2.51 (1.34-4.69) | 0.007 |
| Model 3 | 1.53 (1.08-2.16) | 0.018 | 1 (ref.) | 1.25 (0.74-2.12) | 1.10 (0.65-1.88) | 2.24 (1.22-4.10) | 0.017 |

Cancer-related deaths

| Cancer-related deaths | Doubling in Hcy | p value | Q1 (n = 574) | Q2 (n = 569) | Q3 (n = 574) | Q4 (n = 569) | p for trend |
|----------------------|----------------|---------|--------------|--------------|--------------|--------------|------------|
| Mortality rate per 1000 person-years | | | | | | | |
| Unadjusted | 5.2 (4.2-6.5) | 2.4 (1.4-4.5) | 4.9 (3.1-8.0) | 5.5 (3.6-8.8) | 11.0 (7.9-15.7) | | |
| Model 1 | 1.93 (1.50-2.49) | <0.001 | 1 (ref.) | 2.02 (0.92-4.44) | 2.27 (1.06-4.85) | 4.60 (2.40-8.83) | <0.001 |
| Model 2 | 1.35 (0.99-1.83) | 0.056 | 1 (ref.) | 1.38 (0.6-3.13) | 1.26 (0.55-2.88) | 2.12 (1.07-4.2) | 0.030 |
| Model 3 | 1.50 (0.94-2.40) | 0.087 | 1 (ref.) | 0.96 (0.40-2.35) | 0.92 (0.35-2.39) | 2.05 (0.90-4.69) | 0.096 |

*Weighted mortality was expressed as a rate per 1000 person-years of follow-up and 95% CI. *HR (95% CI) was estimated by weighted Cox regression analyses. Model 1 was adjusted for age and sex (n = 2,286). Model 2 was additionally adjusted for race/ethnicity, smoking, BMI, hypertension, cancer, CVD, TC/HDL-C ratio, lipid-lowering agents, antiplatelet, vitamin B12, eGFR, Hba1c, metformin, duration of diabetes, UACR, ACEI/ARBs, and diabetic complications (n = 2,050).
Figure 3: Stratification analysis on HRs of total mortality per doubling of Hcy. HR (95% CI) was estimated with weighted Cox regression adjusted for model 2 except the corresponding subgroup factors. *p value < 0.05 represents a significance for the interaction of stratification factors for the association of a doubling in Hcy with mortality.

Figure 4: The receiver operating characteristic curves of Hcy and CRP to predict 10-year all-cause mortality risk in diabetic adults.
Table 4: Predictive value of baseline Hcy for 10-year total and heart-related mortality in patients with preexisting diabetes.

| Model                  | Reference   | Reference +Hcy | Reference +CRP |
|------------------------|-------------|----------------|---------------|
| Likelihood ratio test  | —           | <0.001         | 0.074         |
| AIC                    | 11118.2     | 11106.1        | 11117.0       |
| BIC                    | 11185.9     | 11179.5        | 11190.3       |
| Harrell’s C-index      | 0.763       | 0.766          | 0.764         |
| NRI                    | —           | 0.253          | 0.188         |
| IDI                    | —           | 0.011          | 0.003         |

*Reference model included age, sex, smoking status, BMI, hypertension, cancer, cardiovascular disease, the ratio of TC/HDL-C, eGFR, UACR, HbAc1, diabetic duration, and diabetic complications. All statistics were estimated based on the unweighted logistic regression analysis. Each additional model is compared to the reference model. AIC: Akaike information criterion; BIC: Bayesian information criterion; CRP: C-reactive protein; Hcy: homocysteine; IDI: integrated discrimination improvement; NRI: net reclassification index.

The biological role of Hcy in the progression of diabetes and diabetic complications was demonstrated by a large number of studies. Hcy accumulation may be involved in the development of diabetes via aggravating insulin resistance (IR) and macro-/microvascular endothelial dysfunction [30, 31]. The underlying mechanism could be related to the oxidative stress effect of homocysteine in the cardiovascular system [17, 32]. In our findings, the association between serum Hcy and mortality risk was mainly attributed to the increased cardiovascular deaths. That may be explained by previous numerous biological studies that Hcy can lead to the pathogenesis of CVD via multiple mechanisms such as its disadvantageous effects on smooth muscle cells and endothelium with subsequent alterations in arterial function and structure [33, 34]. Oxidative stress as a critical mediator of Hcy increase may promote the proliferation of vascular smooth muscle cells, endothelial dysfunction, platelet activation, and decreased elasticity of the arterial wall [35]. The development and progression of diabetes have been linked with redox disorder, and therefore, serum Hcy seems to be promising biomarker for the risk stratification in diabetic patients [36]. Interestingly, our findings suggested that based on traditional risk factors, Hcy may improve risk stratification of 10-year mortality in diabetic patients beyond inflammatory marker C-reactive protein. The prognostic implication of Hcy in diabetic patients warrants further investigation.

However, whether Hcy is a mediator of cardiovascular pathophysiology remains controversial [10, 33]. Some studies have proved that lowering Hcy cannot yield significant cardiovascular benefits [37]. Part of the explanation may be that the advancement in cardiovascular secondary prevention has masked the benefits of reducing Hcy. Indeed, numerous biological studies demonstrated that Hcy participated in the redox disorder associated with diabetes and diabetic complications and reduced Hcy delayed oxidative stress of multiple organ injuries in mice [36, 38]. Clinical evidence also supported that the level of oxidative stress was significantly elevated in diabetic patients [17]. Further research is needed to prove the direct link between Hcy intervention and diabetes progression. A fundamental part of these studies should identify whether elevated Hcy is the cause or the result of the pathophysiological change and whether it is related to the progression of cardiovascular complications in diabetes. Altogether, taking into account the broad availability and cost-efficacy of Hcy detection, it could be a good screening biomarker for poor prognosis among diabetic patients.

The strengths of our analysis include the use of nationally representative data of US adults with diabetes, a prospective study design, and validated protocols. Several limitations need to be considered. First, causality cannot be concluded due to the observational study design. The genetic variants in Hcy metabolism-related genes may provide more information for the causal relationship between Hcy and outcomes. Second, information on distinguishing type 1 and type 2 diabetes was lacking in this study, whereas oxidative stress is one of the common characteristics in both type 1 and type 2 diabetes. Our findings underline Hcy as a potentially promising biomarker for the progression and poor outcomes of diabetes. Third, although potential confounding factors were adjusted to the greatest extent, we could not completely rule out the possibility of residual confounding unknown. Forth, Single detection of serum Hcy may not accurately assess the long-term levels during the follow-up, but that tends to attenuate results toward the null. Fifth, due to the lower incidence of stroke-related deaths, the association between serum Hcy and stroke-specific mortality should be interpreted cautiously and needs further validation [39].

In conclusion, we found that higher serum Hcy concentrations were significantly associated with increased all-cause and cardiovascular mortality in a nationally representative sample of diabetic adults. Moreover, serum Hcy improves risk stratification in patients with diabetes outmatched C-reactive protein. These findings support further investigation of the potential benefits of lowering Hcy in the prevention of premature death among diabetes patients.

**Data Availability**

All data used were obtained from the NHANES study (http://www.cdc.gov/nchs/nhanes). Data are available on reasonable request from the website or authors.

**Conflicts of Interest**

There are no conflicts of interest to declare.
Authors’ Contributions

Hai Tian and Yanjiao Shen conceived and designed the study. Zili Ma and Dong Li developed the protocols. Kegong Chen and Wei Chen organized all data. Chang Liu and XingPei Jiang analyzed and visualized the results. Kegong Chen and Jingtong Lu wrote the manuscript and reviewed and edited the manuscript. Hai Tian and Yanjiao Shen take the responsibility for the integrity and accuracy of this analysis. Kegong Chen, Jingtong Lu, and Wei Chen contributed equally to this work.

Acknowledgments

The authors thank all the participants and investigators in the NHANES study for their outstanding contributions. This work was supported by the National Natural Science Foundation of China (Nos. 81770347 and 81401203), the Funding for the Reserve Leader of Heilongjiang Provincial Leading Talent Echelon, and the Key Laboratory of Education Ministry for Myocardial Ischemia Open Research Foundation (KF201919).

Supplementary Materials

Supplementary Table 1: the association of Hcy with mortality due to stroke and cardiac disease in adults with diabetes. Supplementary Table 2: sensitivity analysis for the association between serum Hcy and mortality after excluding probable type 1 diabetes. Supplementary Table 3: sensitivity analysis for the association between serum Hcy and mortality after excluding participants with first-diagnosed diabetes. Supplementary Table 4: the association between serum homocysteine and mortality in diabetic adults. (Supplementary Materials)

References

[1] Y. Zheng, S. H. Ley, and F. B. Hu, “Global aetiology and epidemiology of type 2 diabetes mellitus and its complications,” Nature Reviews Endocrinology, vol. 14, no. 2, pp. 88–98, 2018.
[2] Y. Li, D. Teng, X. Shi et al., “Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study,” BMJ, vol. 369, article m997, 2020.
[3] I. J. Biphagen, W. E. Boertien, A. Alkhalaf et al., “Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31),” Diabetes Care, vol. 36, no. 10, pp. 3201–3207, 2013.
[4] American Diabetes Association, “4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes—2020,” Diabetes Care, vol. 43, Supplement 1, pp. S37–S47, 2020.
[5] J. Ghouse, M. W. Skov, J. K. Kanters et al., “Visit-to-visit variability of hemoglobin A1c in people without diabetes and risk of major adverse cardiovascular events and all-cause mortality,” Diabetes Care, vol. 42, no. 1, pp. 134–141, 2019.
[6] C. V. Rotbain, S. Theilade, S. A. Winther et al., “Soluble urokinase plasminogen activator receptor predicts cardiovascular events, kidney function decline, and mortality in patients with type 1 diabetes,” Diabetes Care, vol. 42, no. 6, pp. 1112–1119, 2019.
[7] R. Moretti and P. Caruso, “The controversial role of homocysteine in neurology: from labs to clinical practice,” International Journal of Molecular Sciences, vol. 20, no. 1, p. 231, 2019.
[8] A. D. Smith and H. Refsum, “Homocysteine, B vitamins, and cognitive impairment,” Annual Review of Nutrition, vol. 36, no. 1, pp. 211–239, 2016.
[9] D. Djuric, V. Jakovljevic, V. Zivkovic, and I. Srejovic, “Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems,” Canadian Journal of Physiology and Pharmacology, vol. 96, no. 10, pp. 991–1003, 2018.
[10] E. A. Ostrakhovitch and S. Tabibzadeh, “Homocysteine and age-associated disorders,” Ageing Research Reviews, vol. 49, pp. 144–164, 2019.
[11] H. Y. Peng, C. F. Man, J. Xu, and Y. Fan, “Elevated homocysteine levels and risk of cardiovascular and all-cause mortality: a meta-analysis of prospective studies,” Journal of Zhejiang University. Science. B, vol. 16, no. 1, pp. 78–86, 2015.
[12] T. Rehman, M. A. Shabbir, M. Inam-Ur-Raheem et al., “Cysteine and homocysteine as biomarker of various diseases,” Food Science & Nutrition, vol. 8, no. 9, pp. 4696–4707, 2020.
[13] A. Jamroz-Wisniewska, J. Beltowski, G. Wojcicka, H. Bartosik-Psujek, and K. Rejdak, “Cladribine treatment improved homocysteine metabolism and increased total serum antioxidant activity in secondary progressive multiple sclerosis patients,” Oxidative Medicine and Cellular Longevity, vol. 2020, Article ID 1654754, 7 pages, 2020.
[14] S. S. Soedamah-Muthu, N. Chaturvedi, T. Teerlink, B. Idzior-Walus, J. H. Fuller, and C. D. Stelhouwer, “Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study,” Journal of Internal Medicine, vol. 258, no. 5, pp. 450–459, 2005.
[15] H. C. Looker, A. Fagot-Campagna, E. W. Gunter et al., “Homocysteine and vitamin B12 concentrations and mortality rates in type 2 diabetes,” DiabetesMetabolism Research and Reviews, vol. 23, no. 3, pp. 193–201, 2007.
[16] A. Schaffer, M. Verdol, L. Barbieri, E. Cassetti, H. Suryaprana, and G. De Luca, “Impact of diabetes on homocysteine levels and its relationship with coronary artery disease: a single-centre cohort study,” Annals of Nutrition and Metabolism, vol. 68, no. 3, pp. 180–188, 2016.
[17] E. Muzurovic, I. Kraljevic, M. Solak, S. Dragnic, and D. P. Mikhalidis, “Homocysteine and diabetes: role in macrovascular and microvascular complications,” Journal of Diabetes and its Complications, vol. 35, no. 3, article 107834, 2021.
[18] H. You, K. Chen, P. Han, C. Yue, and X. Zhao, “U-shaped relationship between cardiovascular mortality and serum uric acid may be attributed to stroke- and heart-specific mortality, respectively, among hypertensive patients: a nationally representative cohort study,” Medical Science Monitor, vol. 27, article e928937, 2021.
[19] S. Wang, Y. Liu, J. Liu et al., “Mitochondria-derived methyl-malonic acid, a surrogate biomarker of mitochondrial dysfunction and oxidative stress, predicts all-cause and cardiovascular mortality in the general population,” Redox Biology, vol. 37, article 101741, 2020.
[20] V. Veeranna, S. K. Zalawadiya, A. Niraj et al., “Homocysteine and reclassification of cardiovascular disease risk,” Journal of...
the American College of Cardiology, vol. 58, no. 10, pp. 1025–1033, 2011.

[21] S. Wang, W. Tian, Y. Liu et al., “Temporal trend of circulating trans-fatty acids and risk of long-term mortality in general population,” Clinical Nutrition, vol. 40, no. 3, pp. 1095–1101, 2021.

[22] S. Wang, Y. Wang, X. Wan et al., “Cobalamin intake and related biomarkers: examining associations with mortality risk among adults with type 2 diabetes in NHANES,” Diabetes Care, vol. 45, no. 2, pp. 276–284, 2022.

[23] S. Wang, Y. Liu, H. Cai et al., “Decreased risk of all-cause and heart-specific mortality is associated with low-fat or skimmed milk consumption compared with whole milk intake: a cohort study,” Clinical Nutrition, vol. 40, no. 11, pp. 5568–5575, 2021.

[24] X. Wu, L. Zhang, Y. Miao et al., “Homocysteine causes vascular endothelial dysfunction by disrupting endoplasmic reticulum redox homeostasis,” Redox Biology, vol. 20, pp. 46–59, 2019.

[25] S. Shiao, A. Lie, and C. H. Yu, “Meta-analysis of homocysteine-related factors on the risk of colorectal cancer,” Oncotarget, vol. 9, no. 39, pp. 25681–25697, 2018.

[26] A. Gasecka, D. Siwik, M. Gajewska et al., “Early biomarkers of neurodegenerative and neurovascular disorders in diabetes,” Journal of Clinical Medicine, vol. 9, no. 9, p. 2807, 2020.

[27] R. Fan, A. Zhang, and F. Zhong, “Association between Homocysteine levels and all-cause mortality: a dose- response meta-analysis of prospective studies,” Scientific Reports, vol. 7, no. 1, p. 4769, 2017.

[28] M. Zhu, M. Mao, and X. Lou, “Elevated homocysteine level and prognosis in patients with acute coronary syndrome: a meta-analysis,” Biomarkers, vol. 24, no. 4, pp. 309–316, 2019.

[29] G. Ndrepepa, A. Kastrati, S. Braun et al., “A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease,” Clinica Chimica Acta, vol. 373, no. 1-2, pp. 70–76, 2006.

[30] M. T. Mursleen and S. Riaz, “Implication of homocysteine in diabetes and impact of folate and vitamin B12 in diabetic population,” Diabetes and Metabolic Syndrome: Clinical Research and Reviews, vol. 11, Supplement 1, pp. S141–S146, 2017.

[31] Y. Hu, Y. Xu, and G. Wang, “Homocysteine levels are associated with endothelial function in newly diagnosed type 2 diabetes mellitus patients,” Metabolic Syndrome and Related Disorders, vol. 17, no. 6, pp. 323–327, 2019.

[32] M. Lindschinger, F. Tatzber, W. Schimetta et al., “A randomized pilot trial to evaluate the bioavailability of natural versus synthetic vitamin B complexes in healthy humans and their effects on homocysteine, oxidative stress, and antioxidant levels,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 6082613, 14 pages, 2019.

[33] L. Hannibal and H. J. Blom, “Homocysteine and disease: causal associations or epiphenomenons?,” Molecular Aspects of Medicine, vol. 53, pp. 36–42, 2017.

[34] P. Ganguly and S. F. Alam, “Role of homocysteine in the development of cardiovascular disease,” Nutrition Journal, vol. 14, no. 1, 2015.

[35] S. Zhang, Y. Y. Bai, L. M. Luo, W. K. Xiao, H. M. Wu, and P. Ye, “Association between serum homocysteine and arterial stiffness in elderly: a community-based study,” Journal of Geriatric Cardiology, vol. 11, no. 1, pp. 32–38, 2014.

[36] T. Bito, T. Misaki, Y. Yabuta, T. Ishikawa, T. Kawano, and F. Watanabe, “Vitamin B12 deficiency results in severe oxida-